title: Highlights from the 98th annual meeting of the American Urological Association Chicago, IL.
authors.forename: Heather
authors.initials: H
authors.lastname: DeGrendele
authors.forename: Jennifer
authors.initials: J
authors.lastname: Klem
authors.forename: Mary
authors.initials: M
authors.lastname: Hightower
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D003226:Congresses as Topic; D018849:Controlled Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000453:epidemiology; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy*; D012955:Societies, Medical; D016019:Survival Analysis; D014055:Tomography, Emission-Computed / Q000379:methods; D016896:Treatment Outcome; D014481:United States; D014572:Urology; D000077211:Zoledronic Acid
chemical_list: D000726:Androgen Antagonists; D019496:Cancer Vaccines; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D016178:Granulocyte-Macrophage Colony-Stimulating Factor